ENGN
enGene Therapeutics Inc.
$1.78
+0.02 (+1.14%)
At close · Jul 2
Market Cap
$119.24M
Shares
66,989,466
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.78
Open$1.79
Day$1.76–1.81
52W$1.40–12.25
Avg vol 30d1.0M
Short int1.4M · 2.1% float · 1.6d
Short vol41%
Last earningsJun 15, 2026
DataFeb 2022–Jul 2026
Filing10-Q · Jun 15
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−74% below
−
Price vs 50-day avg
−41% below
◦
RSI (14)
38 · neutral
+
MACD trend
positive
−
52-week position
4% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $3 › 200d $7 — 200d above 50d
+
Institutional flow
+4% holders QoQ · +12 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
2.08% of float · ▼ -14.3% MoM · 1.6 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
59 holders — near 2-yr high, broad support
Fundamentals
Strong
+
EPS growth
+57% Y/Y
−
Free cash flow
$-100.7M
+
Valuation
P/E 0.8 · below peers
+
Balance sheet
net cash $50.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Sep 21, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Jul 31, 2026
Est
filed Jun 15, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−74% below
Bearish
Price vs 50-day avg
−41% below
Bearish
RSI (14)
38 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
4% · near low
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.08% of float · ▼ -14.3% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
59 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 4%
52-wk high $12
vs 200-day avg -74%
vs 50-day avg -41%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENGN
this stock
enGene Therapeutics Inc.
|
$119.24M | -80.3% | — | 0.8 | 2.1% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENGN | +0.6% | +6.6% | -79.1% | +2.9% | -80.3% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -0.9% | +7.8% | -87.1% | +3.2% | -89.5% |